Last reviewed · How we verify
Matching Placebo Tablets
A matching placebo tablet contains inert ingredients designed to be indistinguishable from an active pharmaceutical formulation for use as a control in clinical trials.
At a glance
| Generic name | Matching Placebo Tablets |
|---|---|
| Also known as | Placebo |
| Sponsor | Vyne Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Matching placebos are used in blinded clinical trials to maintain study integrity by ensuring neither participants nor some study staff know who receives active drug versus control. The placebo is formulated to match the appearance, taste, and administration schedule of the active comparator, allowing for valid efficacy and safety assessment without bias from expectation effects.
Approved indications
Common side effects
Key clinical trials
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis (PHASE3)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) (PHASE3)
- Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies (PHASE1)
- Effects of NAC on Symptoms of CHR Patients (NA)
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |